| Not Yet Recruiting | eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation NCT07469592 | University of Miami | N/A |
| Suspended | CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome NCT05617625 | Guenther Koehne | Phase 2 |
| Not Yet Recruiting | TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCT NCT07302776 | Stanford University | Phase 1 |
| Not Yet Recruiting | Pacritinib With Aza for Upfront Myelodysplastic Syndrome NCT07387354 | Thomas Jefferson University | Phase 1 / Phase 2 |
| Recruiting | Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years NCT06303193 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan a NCT07493538 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Not Yet Recruiting | Clonal Hematopoiesis of Immunological Significance NCT05969821 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloprolife NCT07071155 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | EARLY_Phase 1 |
| Recruiting | Ascorbate in Myelodysplastic Syndrome NCT07283900 | Prajwal Dhakal | Phase 2 |
| Not Yet Recruiting | IFN-α in Relapse Prevention. NCT07449286 | Peking University People's Hospital | Phase 2 |
| Not Yet Recruiting | A Study of TAK-226 for Transfusion-Dependent Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndr NCT07319845 | Takeda | Phase 2 |
| Recruiting | Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS NCT07270978 | University of Virginia | Phase 1 |
| Suspended | Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic NCT03184935 | Sclnow Biotechnology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Le NCT07216443 | Orca Biosystems, Inc. | Phase 2 |
| Recruiting | Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT NCT06551584 | Stanford University | Phase 1 |
| Recruiting | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia NCT06599762 | University of Manitoba | Phase 2 |
| Recruiting | HEME Home Transfusion Program NCT06487247 | Dana-Farber Cancer Institute | N/A |
| Enrolling By Invitation | Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study NCT07102849 | National Heart, Lung, and Blood Institute (NHLBI) | — |
| Recruiting | Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT NCT07183878 | First Affiliated Hospital of Zhejiang University | N/A |
| Recruiting | Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood NCT06904482 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory Myelodysplastic Syndromes NCT06923488 | West Virginia University | Phase 1 / Phase 2 |
| Recruiting | Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants NCT07019155 | National Cancer Institute (NCI) | — |
| Recruiting | Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by T NCT06918834 | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 |
| Recruiting | Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies NCT07044544 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Venetoclax-containing Therapy Combined With Microtransplant for Intermediate-risk and Higher MDS NCT07238686 | Beijing 302 Hospital | Phase 2 |
| Recruiting | Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations NCT06630221 | Abhay Singh, MD MPH | Phase 2 |
| Recruiting | A Study of Momelotinib in Participants With Low-risk Myelodysplastic Syndrome NCT06847867 | GlaxoSmithKline | Phase 2 |
| Recruiting | Home Blood Transfusions NCT07121140 | Thomas Jefferson University | N/A |
| Recruiting | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Synd NCT06499285 | Takeda | Phase 3 |
| Recruiting | Mosaic Trial for Stem Cell Transplant Recipients NCT06960993 | Northwestern University | N/A |
| Recruiting | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy NCT06047886 | University of Alabama at Birmingham | Phase 1 |
| Active Not Recruiting | Treatment Patterns and Outcomes in Patients With Lower-risk Myelodysplastic Syndromes Treated With Luspatercep NCT07073690 | Bristol-Myers Squibb | — |
| Recruiting | Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant NCT06315309 | University of Alabama at Birmingham | Phase 2 |
| Withdrawn | Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HM NCT05766514 | University of Florida | Phase 2 |
| Recruiting | OURA Ring Wearable Testing in MDS Patients: a Feasibility and Discovery Pilot Study NCT06270771 | Sunnybrook Health Sciences Centre | — |
| Recruiting | A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome NCT06304103 | Kind Pharmaceuticals LLC | Phase 2 |
| Recruiting | ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis NCT06680661 | Leland Metheny | Phase 2 |
| Recruiting | Ferroptosis Study in SF3B1-mutant Myelodysplastic Syndromes (FerMDS) NCT05924074 | University Hospital, Bordeaux | N/A |
| Recruiting | Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care NCT05745285 | University of Miami | N/A |
| Recruiting | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA NCT06802315 | University of Illinois at Chicago | Phase 2 |
| Recruiting | Iadademstat With Hypomethylating Agent in Patients With Myelodysplastic Syndrome NCT06502145 | Medical College of Wisconsin | Phase 1 |
| Not Yet Recruiting | ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute NCT06463327 | TC Biopharm | Phase 1 |
| Enrolling By Invitation | A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring NCT06788509 | Janssen Research & Development, LLC | Phase 1 |
| Not Yet Recruiting | TMLI Plus Chemotherapy in High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia NCT06598969 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 2 |
| Withdrawn | A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants NCT05367401 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Recruiting | A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Signifi NCT06566742 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry NCT06569095 | Peking University People's Hospital | — |
| Recruiting | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML NCT06594445 | Masonic Cancer Center, University of Minnesota | Phase 1 |
| Completed | A Study to Evaluate Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Patients With Lower-R NCT07075406 | Bristol-Myers Squibb | — |
| Not Yet Recruiting | A Study of HS-20106 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes NCT06594965 | Hansoh BioMedical R&D Company | Phase 2 |
| Not Yet Recruiting | TMLI/Fludarabine/Melphalan Conditioning for Allogeneic Transplantation in High-risk Myelodysplastic Syndrome o NCT06602323 | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Phase 2 |
| Recruiting | Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of P NCT06439199 | Nantes University Hospital | — |
| Recruiting | Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplasti NCT06529731 | Sawa Ito, MD | Phase 2 |
| Withdrawn | Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant NCT06337331 | Northside Hospital, Inc. | Phase 2 |
| Completed | A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Pa NCT06851065 | Bristol-Myers Squibb | — |
| Recruiting | VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS NCT06536959 | Beijing 302 Hospital | Phase 2 |
| Recruiting | BeFluBu vs FluBuRux Conditioning in Haploidentical HCT NCT06477549 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrom NCT06501196 | BlossomHill Therapeutics | Phase 1 |
| Recruiting | PTCy and ATG for MSD and MUD Transplants NCT06299462 | Instituto Nacional de Cancer, Brazil | Phase 1 / Phase 2 |
| Recruiting | A Study to Evaluate the MNV-201 in Patients With Low Risk MDS NCT06465160 | Minovia Therapeutics Ltd. | Phase 1 |
| Recruiting | A Study of GLB-001 in Patients With Myeloid Malignancies NCT06378437 | Hangzhou GluBio Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen NCT06532084 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | A Telehealth Advance Care Planning Intervention NCT05875805 | University of Rochester | N/A |
| Recruiting | Vitamin A and D Supplementation in Allogeneic HCT NCT06508099 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Recruiting | Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML NCT05986240 | Montefiore Medical Center | Phase 1 |
| Recruiting | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignan NCT05800210 | University of Florida | Phase 2 |
| Recruiting | Study of REM-422 in Patients With AML or Higher Risk MDS NCT06297941 | Remix Therapeutics | Phase 1 |
| Recruiting | Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transpla NCT06462365 | Tr1X, Inc. | Phase 1 |
| Not Yet Recruiting | Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS NCT06050941 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Recruiting | TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies NCT06206174 | Shenzhen TargetRx Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | Evaluate the Efficacy and Safety of Allogeneic Haematopoietic Stem Cell Transplantation With FBM Conditioning NCT06247917 | Ruijin Hospital | Phase 2 |
| Unknown | A Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M Score NCT06279338 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Recruiting | A Pilot, Open-Label Study of Luspatercept for Patients With Lower Risk Myelodysplastic Syndromes (MDS) NCT06113302 | M.D. Anderson Cancer Center | Phase 2 |
| Unknown | Sirolimus+Abatacept+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are In NCT06279494 | Peking University People's Hospital | Phase 1 / Phase 2 |
| Recruiting | Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (M NCT05483010 | Washington University School of Medicine | Phase 2 |
| Recruiting | Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform NCT06999954 | Shwachman-Diamond Syndrome Alliance Inc | — |
| Not Yet Recruiting | Upfront Related Donor Transplantation in Patients With Myelodisplatic Syndrome : a Phase 2 Trial NCT06235398 | Assistance Publique - Hôpitaux de Paris | Phase 2 |
| Not Yet Recruiting | Role of BMP Pathway in MDS Progression NCT06175923 | Hospices Civils de Lyon | — |
| Recruiting | Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation NCT06138587 | Dana-Farber Cancer Institute | Phase 1 |
| Recruiting | A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Hi NCT06146257 | GluBio Therapeutics Inc. | Phase 1 |
| Recruiting | Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT NCT06130579 | Peking University People's Hospital | Phase 2 |
| Recruiting | Unified platforM for a Better integRal Evaluation of MyeLodyspLastic Syndromes in SpAin-Strategy for Unravelin NCT06379945 | Instituto de Investigación Biomédica de Salamanca | — |
| Active Not Recruiting | A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic NCT05883956 | Otsuka Australia Pharmaceutical Pty Ltd | Phase 3 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantati NCT06001385 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Active Not Recruiting | Haploidentical Hematopoietic Cell Transplantation Using TCR Alpha/Beta and CD19 Depletion NCT05236764 | Baylor College of Medicine | N/A |
| Active Not Recruiting | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Child NCT06475820 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 / Phase 3 |
| Active Not Recruiting | Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Tr NCT05968963 | University of Miami | N/A |
| Terminated | Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes NCT05918055 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Withdrawn | High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD NCT05895201 | Indiana University | Phase 1 / Phase 2 |
| Unknown | Safety and Efficacy of Unrelated Umbilical Cord Blood Microtransplantation in Patients With Higher-risk MDS NCT06109064 | Anhui Provincial Hospital | Phase 2 |
| Recruiting | ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic S NCT05949684 | Bristol-Myers Squibb | Phase 3 |
| Recruiting | Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Mali NCT05991908 | Shanghai Jiao Tong University School of Medicine | Phase 3 |
| Recruiting | Prolonged Ultra Low-dose Decitabine Plus Venetoclax for Primary Diagnosed Elderly AMLK/MDS NCT06046313 | First Affiliated Hospital of Zhejiang University | Phase 2 |
| Active Not Recruiting | PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes NCT06091267 | Otsuka Beijing Research Institute | Phase 1 / Phase 2 |
| Terminated | A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokine NCT06021600 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | A Study to Assess Luspatercept in Lower-risk Myelodysplastic Syndrome Participants NCT06045689 | Bristol-Myers Squibb | Phase 3 |
| Active Not Recruiting | Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant NCT04167683 | Rigshospitalet, Denmark | — |
| Withdrawn | A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as NCT05201183 | Naoyuki G. Saito, M.D., Ph.D. | Phase 1 / Phase 2 |
| Active Not Recruiting | Muscle Dysfunction in Patients With Haematological Diseases NCT05150561 | Rigshospitalet, Denmark | — |
| Unknown | Clinical Trial Evaluating the Safety of the TQB2928 Injection Combination Therapy NCT06008405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 |
| Unknown | Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS NCT06004765 | Peking Union Medical College Hospital | Phase 4 |
| Not Yet Recruiting | A Single-arm Trial of Roxadustat Combined With Retinoic Acid in the Treatment of Refractory Low-risk MDS NCT06020833 | Peking Union Medical College Hospital | Phase 1 / Phase 2 |
| Unknown | Roxadustat Combined With Luspatercept Versus Luspatercept Monotherapy in the Treatment of Refractory MDS-RS NCT06006949 | Peking Union Medical College Hospital | Phase 4 |
| Unknown | A Study of TQB3454 Tablets in Patients With Blood Tumors NCT06218771 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 1 / Phase 2 |
| Active Not Recruiting | Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients NCT05823571 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Terminated | A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to V NCT05835011 | Astex Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan f NCT05807932 | Heinrich-Heine University, Duesseldorf | Phase 1 / Phase 2 |
| Unknown | Study of BC3402 in Combination With Azacitidine in Patients With MDS and CMML NCT05970822 | Biocity Biopharmaceutics Co., Ltd. | Phase 1 |
| Active Not Recruiting | Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy NCT05583552 | GCP-Service International West GmbH | Phase 2 |
| Recruiting | Clinical Registration Study of Haplo-HSCT for Elderly Patients With Acute Leukemia/ Myelodysplastic Syndrome NCT05902416 | Peking University People's Hospital | — |
| Recruiting | Allo HSCT Using RIC and PTCy for Hematological Diseases NCT05805605 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Recruiting | A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes NCT05732103 | Chordia Therapeutics, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabi NCT05796570 | Franziska Wachter | Phase 2 |
| Not Yet Recruiting | Lifestyle-modifying Interventions in Low-risk MDS Patients NCT05433805 | Technische Universität Dresden | N/A |
| Recruiting | Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors NCT05194397 | Children's Hospital of Philadelphia | Phase 2 |
| Recruiting | Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms NCT05732961 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Unknown | A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MD NCT05641259 | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1 |
| Active Not Recruiting | Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are NCT05201066 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | Collection of Samples of Bone Marrow Aspiration From Patients With Myelodysplastic Syndrome NCT06144515 | Minovia Therapeutics Ltd. | — |
| Recruiting | Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative NCT05588154 | National Cancer Institute (NCI) | — |
| Withdrawn | Calprotectin, a Biomarker of COVID-19 Severity (CALPRO) NCT04953312 | Assistance Publique - Hôpitaux de Paris | N/A |
| Withdrawn | Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine NCT05246384 | Rhizen Pharmaceuticals SA | Phase 1 / Phase 2 |
| Recruiting | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With NCT04953910 | Taiho Oncology, Inc. | Phase 1 |
| Recruiting | Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation NCT04935684 | University Hospital, Clermont-Ferrand | Phase 2 |
| Active Not Recruiting | A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo NCT05469737 | Bristol-Myers Squibb | Phase 2 / Phase 3 |
| Recruiting | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS NCT05636514 | Clinical Hub for Interventional Research (CHOIR) | Phase 1 |
| Terminated | BMS-986253 in Myelodysplastic Syndromes NCT05148234 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS NCT05457010 | Arcellx, Inc. | Phase 1 |
| Recruiting | A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS NCT05788679 | Karolinska University Hospital | Phase 2 |
| Recruiting | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of NCT05601726 | Advanced BioDesign | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS) NCT05490446 | Agios Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/In NCT05924100 | Associazione Qol-one | Phase 2 |
| Recruiting | A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Tra NCT05473910 | TScan Therapeutics, Inc. | Phase 1 |
| Recruiting | Biocollection in MyeloDysplastic Syndrome (P-MDS) NCT04869683 | University Hospital, Brest | N/A |
| Recruiting | Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Tra NCT05384691 | University of Leipzig | Phase 2 |
| Recruiting | A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacit NCT05365035 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A First in Human Study of AUR 103 Calcium to Evaluate Safety, Pharmacokinetics and Pharmacodynamics NCT05607199 | Aurigene Discovery Technologies Limited | Phase 1 |
| Suspended | Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbet NCT05400122 | David Wald | Phase 1 |
| Withdrawn | Cryopreserved MMUD BM With PTCy for Hematologic Malignancies NCT05170828 | Ossium Health, Inc. | Phase 1 |
| Active Not Recruiting | Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibito NCT05515029 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Recruiting | Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS NCT05350748 | National Cancer Institute (NCI) | — |
| Terminated | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lympho NCT05358808 | TC Biopharm | Phase 2 |
| Completed | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects NCT06469138 | BerGenBio ASA | Phase 1 |
| Recruiting | Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematologica NCT05444348 | Christoffer Johansen | N/A |
| Recruiting | Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS NCT05434598 | Washington University School of Medicine | N/A |
| Active Not Recruiting | Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms NCT05455294 | Jacqueline Garcia, MD | Phase 1 |
| Recruiting | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies NCT05362773 | MacroGenics | Phase 1 |
| Unknown | Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study. NCT05392647 | Tongji Hospital | Phase 2 |
| Withdrawn | Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS NCT04893915 | Washington University School of Medicine | Phase 2 |
| Unknown | Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantat NCT05005299 | Melbourne Health | Phase 1 |
| Recruiting | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia NCT05320198 | Disc Medicine, Inc | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard o NCT05428969 | Faron Pharmaceuticals Ltd | Phase 1 / Phase 2 |
| Completed | Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Req NCT05298930 | Centre Leon Berard | N/A |
| Recruiting | Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS NCT05342584 | Montefiore Medical Center | Phase 1 |
| Recruiting | Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA NCT05181735 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Recruiting | Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allog NCT04742634 | Washington University School of Medicine | Phase 1 / Phase 2 |
| Terminated | Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients NCT05237713 | University of Leipzig | Phase 2 |
| Active Not Recruiting | COaching and Prehabilitation: Faisability Study in Patients With Acute Myeloid Leukemia and Myelodysplastic Sy NCT03595787 | Institut Paoli-Calmettes | N/A |
| Recruiting | Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML NCT05184842 | Montefiore Medical Center | Phase 2 |
| Terminated | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies NCT05107856 | Prelude Therapeutics | Phase 1 |
| Terminated | Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML NCT05275439 | Shattuck Labs, Inc. | Phase 1 |
| Completed | PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation NCT05120570 | Masonic Cancer Center, University of Minnesota | Phase 1 / Phase 2 |
| Recruiting | Unrelated Umbilical Cord Blood Stem Cell Combined With Azacitidine Based Treatment for Advanced MDS,CMML-2 and NCT05584761 | The First Affiliated Hospital with Nanjing Medical University | Phase 1 / Phase 2 |
| Unknown | Flow Cytometric Analysis of Peripheral Blood Neutrophil Myeloperoxidase Expression for Ruling Out Myelodysplas NCT05175469 | University Hospital, Grenoble | — |
| Recruiting | A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) NCT04988555 | Sumitomo Pharma America, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and NCT05218902 | Bristol-Myers Squibb | — |
| Active Not Recruiting | Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms NCT04902833 | Massachusetts General Hospital | — |
| Terminated | MBG453 in Lower Risk MDS NCT04823624 | Massachusetts General Hospital | Phase 2 |
| Terminated | A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndr NCT05168202 | Bristol-Myers Squibb | Phase 1 |
| Terminated | A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies NCT04937166 | Kahr Medical | Phase 1 |
| Unknown | A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrom NCT05140811 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Phase 1 / Phase 2 |
| Terminated | Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 NCT05178342 | University of Leipzig | Phase 2 |
| Terminated | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatmen NCT04849910 | Vor Biopharma | Phase 1 / Phase 2 |
| Recruiting | Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With NCT04953897 | Taiho Oncology, Inc. | Phase 1 |
| Terminated | First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or NCT05086315 | Sanofi | Phase 1 / Phase 2 |
| Terminated | Interferon γ-Primed Mesenchymal Stromal Cells as Prophylaxis for Acute Graft v Host Disease NCT04328714 | Edwin Horwitz | Phase 1 |
| Terminated | Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory NCT04951778 | Celgene | Phase 1 |
| Suspended | Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients NCT04539236 | Mikkael Sekeres, MD | Phase 1 / Phase 2 |
| Active Not Recruiting | Assessment of Effectiveness and Safety of Luspatercept in Patients Suffering From Lower-risk Myelodysplastic S NCT05181592 | GWT-TUD GmbH | Phase 3 |
| Completed | Population Pharmacokinetic Study Based on Quantitative Pharmacology in Patients With Lenalidomide NCT06069024 | Qianfoshan Hospital | — |
| Terminated | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. NCT04866056 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide NCT04904588 | Center for International Blood and Marrow Transplant Research | Phase 2 |
| Terminated | APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS) NCT04638309 | Aprea Therapeutics | Phase 1 |
| Active Not Recruiting | Inqovi Maintenance Therapy in Myeloid Neoplasms NCT04980404 | Massachusetts General Hospital | Phase 1 |
| Recruiting | Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS NCT04986657 | Washington University School of Medicine | N/A |
| Unknown | Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT NCT05066958 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 1 / Phase 2 |
| Unknown | Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT NCT04764513 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Recruiting | Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft NCT05088356 | Stanford University | Phase 1 |
| Terminated | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple NCT04582539 | Incyte Corporation | Phase 1 / Phase 2 |
| Completed | A Study of E7820 in People With Bone Marrow (Myeloid) Cancers NCT05024994 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (H NCT04973280 | Celgene | — |
| Completed | Removing Transfusion Dependence as a Barrier to Hospice Enrollment NCT05063591 | Adam Olszewski | N/A |
| Recruiting | Hypomemylating Agents Combination With eDC Therapy for Elderly Patients With Myelodysplastic Syndrome NCT04999943 | Affiliated Hospital to Academy of Military Medical Sciences | Phase 1 |
| Terminated | Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS NCT04810611 | Novartis Pharmaceuticals | Phase 1 |
| Recruiting | Protocol For Genomically Profiling, Collecting, Archiving And Distributing Blood And Bone Marrow Specimens Fro NCT04968834 | Dana-Farber Cancer Institute | — |
| Active Not Recruiting | Study of Efficacy and Safety of Eltrombopag in Lower-risk MDS Patients With Platelet Transfusion Dependence NCT04797000 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | A Study of BGB-11417 in Participants With Myeloid Malignancies NCT04771130 | BeiGene | Phase 1 / Phase 2 |
| Withdrawn | Physical Activity in Transfusion Dependent Patients With Myelodysplastic Syndrome NCT04969367 | Thomas Jefferson University | — |
| Withdrawn | A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher NCT04264806 | Janssen Research & Development, LLC | Phase 2 |
| Completed | BST-236 as a Single Agent in Adults With Relapsed or Refractory AML or HR-MDS NCT04827719 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Withdrawn | CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome NCT03929211 | Wake Forest University Health Sciences | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML NCT04730258 | Treadwell Therapeutics, Inc | Phase 1 / Phase 2 |
| Terminated | Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome NCT05263271 | Changchun GeneScience Pharmaceutical Co., Ltd. | Phase 1 |
| Active Not Recruiting | Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA NCT04798339 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Completed | A Telehealth Advance Care Planning Intervention for Older Patients With Acute Myeloid Leukemia and Myelodyspla NCT04745676 | University of Rochester | N/A |
| Terminated | Impact of 2 Transfusion Strategies on Quality of Life of Multitransfused Patients With Low-risk Myelodysplasti NCT03643042 | Lille Catholic University | N/A |
| Unknown | GENOMED4ALL: Improving MDS Classification and Prognosis by AI NCT04889729 | Istituto Clinico Humanitas | — |
| Completed | IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogen NCT04628338 | Sawa Ito, MD | EARLY_Phase 1 |
| Terminated | Thrombosomes® in Bleeding Thrombocytopenic Patients Study NCT04631211 | Cellphire Therapeutics, Inc. | Phase 2 |
| Completed | Interplay Between Immune and Metabolic Programs in Myelodysplastic Syndromes NCT04803721 | University Hospital, Toulouse | — |
| Unknown | Methods of T Cell Depletion Trial (MoTD) NCT04888741 | University of Birmingham | Phase 2 |
| Completed | Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT NCT04629430 | University of Virginia | N/A |
| Recruiting | Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients NCT04587856 | Gruppo Italiano Malattie EMatologiche dell'Adulto | N/A |
| Terminated | Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic S NCT04797780 | Syros Pharmaceuticals | Phase 3 |
| Completed | Post-transplantation Benadamustine and Cyclophosphamide in Patients With Refractory Myeloid Malignancies NCT04943757 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Completed | Benadamustine, Fludarabine and Busulfan Conditioning in Recipients of Haploidentical Stem Cell Transplantation NCT04942730 | St. Petersburg State Pavlov Medical University | Phase 2 |
| Active Not Recruiting | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS NCT04668885 | Case Comprehensive Cancer Center | Phase 2 |
| Completed | CD8 Depleted, Non-engrafting, HLA Mismatched Unrelated Infusion With MDS and Secondary AML NCT04620681 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Recruiting | IS-free Treg HaploHCT NCT04678401 | Dana-Farber Cancer Institute | Phase 1 |
| Active Not Recruiting | NTX-301 in MDS/AML NCT04167917 | University of Alabama at Birmingham | Phase 1 |
| Terminated | Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myelo NCT04095858 | Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Phase 3 |
| Completed | Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat NCT04712942 | University of Leipzig | Phase 2 |
| Unknown | MyPal ePRO-based Early Palliative Care System in Adult Patients With Hematologic Malignancies NCT04370457 | Centre for Research and Technology Hellas | N/A |
| Recruiting | Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms NCT04460950 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Unknown | A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS NCT04358393 | Ascentage Pharma Group Inc. | Phase 1 / Phase 2 |
| Unknown | A Study to Evaluate the Efficacy, Drug Levels and Safety of Luspatercept (ACE-536) for the Treatment of Anemia NCT04477850 | Celgene | Phase 2 |
| Completed | A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) NCT04609826 | Janssen Research & Development, LLC | Phase 1 |
| Recruiting | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies NCT04187703 | Benjamin Tomlinson | EARLY_Phase 1 |
| Recruiting | Study to Evaluate the Safety and Tolerability of EP0042 NCT04581512 | Ellipses Pharma | Phase 1 / Phase 2 |
| Terminated | A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS NCT04477291 | Aptose Biosciences Inc. | Phase 1 |
| Unknown | Haploinsufficiency of the RBM22 and SLU7 Genes in Del(5q) Myelodysplastic Syndromes NCT04701229 | University Hospital, Brest | — |
| Suspended | Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS NCT04485065 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
| Completed | A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies NCT04543305 | Prelude Therapeutics | Phase 1 |
| Terminated | Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome NCT04313881 | Gilead Sciences | Phase 3 |
| Unknown | Idiopathic Chronic Thrombocytopenia of Undetermined Significance : Pathogenesis and Biomarker NCT04003220 | University Hospital, Bordeaux | — |
| Unknown | Could Ki-67 be Used as a Diagnostic or Prognostic Marker in Hemato-oncological Diagnostics? NCT04517175 | Maastricht University | — |
| Completed | IDH2-Post-Allo-Trial for Patients with IDH2-mut Myeloid Neoplasms After Allo-SCT NCT04522895 | Heinrich-Heine University, Duesseldorf | Phase 2 |
| Completed | Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients NCT04676945 | Michael Pfeilstöcker | — |
| Active Not Recruiting | Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS NCT04482894 | University of Virginia | Phase 2 |
| Recruiting | A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Synd NCT04419649 | Takeda | Phase 2 |
| Completed | Haplo Peripheral Blood Sct In GVHD Prevention NCT04473911 | Zachariah Michael DeFilipp | Phase 1 |
| Unknown | Development and Prospective Validation of a Standardized Flow Cytometric Assay of Peripheral Blood Neutrophil NCT04399018 | University Hospital, Grenoble | — |
| Withdrawn | HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation NCT04464889 | Medigene AG | Phase 1 |
| Recruiting | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant NCT03964506 | Omar Aljitawi | EARLY_Phase 1 |
| Recruiting | Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic NCT04245397 | Syntrix Biosystems, Inc. | Phase 1 |
| Terminated | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML NCT05933070 | Inmune Bio, Inc. | Phase 1 |
| Terminated | Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or NCT04266301 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT04402541 | Cleave Therapeutics, Inc. | Phase 1 |
| Unknown | Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations NCT04906031 | First Affiliated Hospital of Jinan University | Phase 2 |
| Recruiting | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With NCT04256317 | Taiho Oncology, Inc. | Phase 2 / Phase 3 |
| Completed | CPX-351 in Higher Risk Myelodysplastic Syndromes NCT04273802 | Groupe Francophone des Myelodysplasies | Phase 1 / Phase 2 |
| Withdrawn | Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosp NCT04361058 | SCRI Development Innovations, LLC | Phase 1 |
| Withdrawn | SNS-301 Monotherapy in High Risk MDS and CMML NCT04217720 | Sensei Biotherapeutics, Inc. | Phase 2 |
| Completed | CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML NCT04151706 | Robert Lowsky | Phase 2 |
| Completed | Biologically Focused Therapy of Treatment-Refractory MDS Patients NCT05245032 | Stanford University | — |
| Completed | Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS NCT04055844 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Withdrawn | A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Pat NCT04044209 | Yale University | Phase 2 |
| Active Not Recruiting | Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogenei NCT03842696 | University of Michigan Rogel Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-tran NCT03533816 | University of Kansas Medical Center | Phase 1 |
| Active Not Recruiting | AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration NCT04263181 | Washington University School of Medicine | — |
| Unknown | Sterile Inflammation and Molecular Aberrations in MDS NCT04313231 | Medical University Innsbruck | — |
| Unknown | Enhanced Palliative Care in MDS and AML NCT04226768 | The University of Hong Kong | N/A |
| Withdrawn | Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute NCT04296214 | Grupo Cooperativo de Hemopatías Malignas | — |
| Completed | Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy NCT04014764 | Notable Labs | — |
| Completed | Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies NCT04191187 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysp NCT04036448 | Celgene | — |
| Active Not Recruiting | Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancie NCT04013685 | Orca Biosystems, Inc. | Phase 1 |
| Active Not Recruiting | Matched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leu NCT04232241 | Universitätsklinikum Hamburg-Eppendorf | Phase 2 |
| Unknown | Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation NCT03836690 | University College, London | Phase 1 |
| Terminated | Early and Low Dose Deferasirox (3.5 mg/kg FCT) to Suppress NTBI and LPI as Early Intervention to Prevent Tissu NCT03920657 | Fondazione Italiana Sindromi Mielodisplastiche-ETS | Phase 2 |
| Enrolling By Invitation | A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) NCT04093570 | Taiho Oncology, Inc. | Phase 2 |
| Unknown | An European Platform for Translational Research in Myelodysplastic Syndromes NCT04174547 | Istituto Clinico Humanitas | — |
| Withdrawn | Pyrimethamine for Intermediate/High-risk Myelodysplastic Syndromes (MDS) NCT03057990 | Montefiore Medical Center | Phase 1 |
| Recruiting | Combining Active and Passive DNA Hypomethylation NCT03999723 | Kirsten Grønbæk | Phase 2 |
| Completed | Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cel NCT03755414 | Washington University School of Medicine | Phase 1 |
| Recruiting | A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation NCT04024761 | Dana-Farber Cancer Institute | Phase 1 |
| Unknown | Screening Gene Mutations in Myeloid Cancers by Next Generation Sequencing to Improve Treatment Results NCT04060485 | National Taiwan University Hospital | — |
| Completed | Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL NCT04053933 | University Hospital, Antwerp | — |
| Completed | ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant NCT03932643 | University of Nebraska | Phase 1 |
| Completed | A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems NCT03814005 | Takeda | Phase 1 |
| Active Not Recruiting | A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT NCT03912064 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702) NCT03904134 | Center for International Blood and Marrow Transplant Research | N/A |
| Terminated | A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Ver NCT03946670 | Novartis Pharmaceuticals | Phase 2 |
| Recruiting | Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune NCT05931718 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | — |
| Completed | An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low NCT03900715 | Celgene | Phase 2 |
| Active Not Recruiting | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher R NCT03927261 | Precigen, Inc | Phase 1 |
| Active Not Recruiting | IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome NCT03503409 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Terminated | AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis NCT03718143 | NYU Langone Health | Phase 2 |
| Active Not Recruiting | Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation NCT03843528 | Johns Hopkins All Children's Hospital | Phase 1 |
| Withdrawn | iCare 2: Personalized Genomic Mutation Informed Treatment of Patients With Myelodysplastic Syndromes NCT03446638 | University of Florida | N/A |
| Recruiting | A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies NCT03802695 | Orca Biosystems, Inc. | Phase 1 |
| Active Not Recruiting | IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome NCT03744390 | Groupe Francophone des Myelodysplasies | Phase 2 |
| Recruiting | A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) NCT03886662 | Lixte Biotechnology Holdings, Inc. | Phase 1 / Phase 2 |
| Completed | A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodyspl NCT03915379 | Janssen Research & Development, LLC | Phase 1 |
| Terminated | A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS NCT03884829 | Cyclacel Pharmaceuticals, Inc. | Phase 1 |
| Recruiting | CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT NCT03810196 | Children's Hospital of Philadelphia | N/A |
| Completed | VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies NCT03885947 | Alla Keyzner | Phase 1 |
| Completed | A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes NCT03746041 | University of Rochester | Phase 1 |
| Recruiting | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Red NCT03852407 | University of Liege | Phase 2 |
| Terminated | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial NCT03735446 | Dana-Farber Cancer Institute | Phase 1 |